Nanox to Announce Third Quarter 2020 Financial and Operating Results on Monday, November 9, 2020
NANO-X IMAGING LTD (NASDAQ: NNOX) will release its third quarter 2020 financial results on November 9, 2020, prior to market opening. A conference call and webcast is scheduled for 8:30 AM ET on the same day, where management will discuss the results. Nanox is focused on innovative medical imaging technology, developing a digital X-ray source aimed at reducing imaging costs. The company seeks collaboration with leading healthcare entities to enhance accessibility to early detection imaging services. For more details, visit www.nanox.vision.
- Scheduled release of Q3 2020 results may enhance investor confidence.
- Potential cost reduction in medical imaging could attract significant market interest.
- Forward-looking statements indicate risks related to COVID-19 pandemic affecting development timelines.
- Uncertainty regarding regulatory approvals for the Nanox.Arc technology.
Management to host conference call and webcast at 8:30 AM ET on November 9, 2020
NEVE ILAN, Israel, Oct. 26, 2020 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announces that it will release its third quarter 2020 financial and operating results for the period ended September 30, 2020 on Monday, November 9, 2020 prior to the start of trading. Management will host a conference call and webcast at 8:30am ET on that day.
Conference call and webcast details
Monday, November 9, 2020 @ 8:30am ET
Investor domestic dial-in: 877-407-0789
Investor international dial-in: 201-689-8562
Webcast link: http://public.viavid.com/index.php?id=141866
About Nanox:
Nanox, founded by the serial entrepreneur Ran Poliakine, is an Israeli corporation that is developing a commercial-grade digital X-ray source designed to be used in real-world medical imaging applications. Nanox believes that its novel technology could significantly reduce the costs of medical imaging systems and plans to seek collaborations with world-leading healthcare organizations and companies to provide affordable, early detection imaging service for all. For more information, please visit www.nanox.vision.
Forward-Looking Statements:
This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of Nanox's research and development, manufacturing and commercialization activities with respect to its X-ray source technology and the Nanox.Arc. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information Nanox has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises could cause a disruption of the development, deployment or regulatory clearance of the Nanox System and adversely impact our business; Nanox's ability to successfully demonstrate the feasibility of its technology for commercial applications; Nanox's expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its X-ray source technology and the Nanox.Arc from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; Nanox's ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.Arc; the market acceptance of the Nanox.Arc and the proposed pay-per-scan business model; Nanox's expectations regarding collaborations with third-parties and their potential benefits; and Nanox's ability to conduct business globally, among others. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Nanox's expectations.
Contact:
Itzhak Maayan
Nanox Imaging
IR@nanox.vision
Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com
FAQ
When will NANO-X IMAGING LTD announce its Q3 2020 financial results?
What time is the NANO-X IMAGING LTD conference call?
How can I access the NANO-X IMAGING LTD webcast?
What is the focus of NANO-X IMAGING LTD's technology?
